Moderna Launches Joint Research for Hantavirus Vaccine, Shares Rise

Moderna announced a collaboration with U.S. and South Korean institutions to develop vaccines that could provide protection against hantaviruses. The company stated that this joint research aims to produce an effective vaccine against hantavirus-related diseases. Following the announcement, Moderna's shares gained 12%. Investors viewed this development as a potential expansion of the company's vaccine portfolio. Hantaviruses are typically transmitted through rodents and can cause severe respiratory infections. Moderna's work in this area is seen as a preventive step against future outbreaks. This is not investment advice.

📊 MRNA — Piyasa Yorumu

▲ up · 60%

Moderna has created a positive catalyst with a new vaccine step. Technical indicators also support this rise; the RSI at 67 is approaching overbought territory but is not yet at a dangerous level. The MACD line is above the signal line and in positive territory, indicating strong short-term momentum. The price is trading above the 20- and 50-day moving averages, signaling a continuation of the uptrend. However, the sharp 17% rise in the last 24 hours may trigger some profit-taking in the short term, so the upside expectation is tempered with cautious optimism.

RSI 14

67.5

MACD

1.96

24h Δ

17.72%

Canlı Grafikler